Cambridge Investment Research Advisors Inc. lifted its position in GlaxoSmithKline (NYSE:GSK) by 10.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 119,385 shares of the pharmaceutical company’s stock after acquiring an additional 11,512 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in GlaxoSmithKline were worth $4,664,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Field & Main Bank acquired a new position in shares of GlaxoSmithKline in the 4th quarter worth approximately $132,000. Amussen Hunsaker Associates LLC acquired a new position in shares of GlaxoSmithKline in the 4th quarter worth approximately $141,000. First Dallas Securities Inc. acquired a new position in shares of GlaxoSmithKline in the 4th quarter worth approximately $142,000. Centaurus Financial Inc. bought a new stake in shares of GlaxoSmithKline in the 1st quarter worth approximately $157,000. Finally, Whittier Trust Co. lifted its holdings in shares of GlaxoSmithKline by 71.0% in the 1st quarter. Whittier Trust Co. now owns 4,520 shares of the pharmaceutical company’s stock worth $177,000 after purchasing an additional 1,876 shares during the last quarter. Institutional investors own 11.10% of the company’s stock.
Shares of GlaxoSmithKline opened at $40.33 on Wednesday, according to Marketbeat.com. The company has a debt-to-equity ratio of 3.90, a quick ratio of 0.40 and a current ratio of 0.61. The company has a market capitalization of $99.25 billion, a P/E ratio of 14.00, a P/E/G ratio of 2.06 and a beta of 0.82. GlaxoSmithKline has a 12-month low of $34.52 and a 12-month high of $44.53.
GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.02). The business had revenue of $10.04 billion for the quarter, compared to the consensus estimate of $10.26 billion. GlaxoSmithKline had a net margin of 3.50% and a return on equity of 144.84%. research analysts forecast that GlaxoSmithKline will post 2.95 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 12th. Shareholders of record on Friday, May 11th will be paid a dividend of $0.5298 per share. This represents a $2.12 annualized dividend and a yield of 5.25%. The ex-dividend date is Thursday, May 10th. GlaxoSmithKline’s payout ratio is currently 72.92%.
Several brokerages recently issued reports on GSK. ValuEngine downgraded GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Friday, May 4th. Zacks Investment Research downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Thursday, April 19th. Deutsche Bank reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, April 9th. BNP Paribas raised GlaxoSmithKline from a “neutral” rating to an “outperform” rating in a report on Wednesday, April 4th. Finally, Morgan Stanley raised GlaxoSmithKline from an “underweight” rating to an “equal weight” rating in a report on Thursday, March 22nd. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $40.21.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.